Financial StabilityThe company reported approximately $47M in cash and cash equivalents at the end of 4Q24, which is believed to be sufficient to fund operations.

Bears Say

Pipeline DevelopmentUncertainties regarding the company's pipeline development and lack of meaningful catalysts contribute to the Neutral rating on LPTX.

Strategic PartnershipsThe company still needs to identify a partner to run the registrational Phase 3 study.

Leap Therapeutics News

Leap Therapeutics Granted Extension by Nasdaq

The latest update is out from Leap Therapeutics ( ($LPTX) ). On March 12, 2025, Leap Therapeutics received...

9d ago

LPTX

Leap Therapeutics Reports Q2 2025 Financial Results

Leap Therapeutics ( ($LPTX) ) has released its Q2 earnings. Here is a breakdown of the information Leap...

1M ago

LPTX

Leap Therapeutics Completes Promising Phase 2 Cancer Study

Leap Therapeutics (($LPTX)) announced an update on their ongoing clinical study. Leap Therapeutics has recently completed a Phase...

2M ago

LPTX

Leap Therapeutics Winds Down R&D Amid Financial Strain

An update from Leap Therapeutics ( ($LPTX) ) is now available. Due to current market conditions and financial...

3M ago

LPTX

Leap Therapeutics to cut workforce by 75%, explore strategic alternatives

Leap is taking additional steps to reduce spending and preserve capital. Over the next two months as the...

3M ago

LPTX

Leap Therapeutics reports updated results from Phase B of DeFianCe study

Leap Therapeutics (LPTX) reported updated results from Part B of the DeFianCe study, a Phase 2 study of...

3M ago

LPTX

Leap Therapeutics Reports Increased Q1 Losses

Leap Therapeutics ( ($LPTX) ) has released its Q1 earnings. Here is a breakdown of the information Leap...

4M ago

LPTX

Leap Therapeutics Reports Positive Clinical Data and Financial Results

Leap Therapeutics ( ($LPTX) ) has released its Q4 earnings. Here is a breakdown of the information Leap...

6M ago

LPTX

Leap Therapeutics reports Q4 EPS (37c) vs. (46c) last year

“In 2024, we continued to advance sirexatamab, our anti-DKK1 antibody, through Phase 2 randomized controlled clinical trials as...

6M ago

LPTX

Leap Therapeutics updated preliminary data from Part B of the DeFianCe study

Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label,...

6M ago

LPTX

LPTX Earnings this Week: How Will it Perform?

Leap Therapeutics (LPTX) is scheduled to report 4th quarter earnings on 03/24/2025. Regarding Q4 estimates, Wall Street analysts...

6M ago

LPTX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

8M ago

CRGX

LPTX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

8M ago

AKRO

ALLK

Apple downgraded, Rivian initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

8M ago

AAPL

LPTX FAQ

What was Leap Therapeutics Inc’s price range in the past 12 months?

Leap Therapeutics Inc lowest stock price was $0.22 and its highest was $4.79 in the past 12 months.

What is Leap Therapeutics Inc’s market cap?

Leap Therapeutics Inc’s market cap is $12.97M.

When is Leap Therapeutics Inc’s upcoming earnings report date?

Leap Therapeutics Inc’s upcoming earnings report date is Nov 17, 2025 which is in 58 days.

How were Leap Therapeutics Inc’s earnings last quarter?

Leap Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.11.

Is Leap Therapeutics Inc overvalued?

According to Wall Street analysts Leap Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Leap Therapeutics Inc pay dividends?

Leap Therapeutics Inc does not currently pay dividends.

What is Leap Therapeutics Inc’s EPS estimate?

Leap Therapeutics Inc’s EPS estimate is -0.24.

How many shares outstanding does Leap Therapeutics Inc have?

Leap Therapeutics Inc has 41,439,530 shares outstanding.

What happened to Leap Therapeutics Inc’s price movement after its last earnings report?

Leap Therapeutics Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -29.412%.

Which hedge fund is a major shareholder of Leap Therapeutics Inc?

Currently, no hedge funds are holding shares in LPTX

Leap Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-183.72%

Trailing 12-Months

Asset Growth

-75.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Leap Therapeutics Inc

Leap Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company operates in the biopharmaceutical sector, specializing in the research and development of novel therapeutics aimed at treating various types of cancer. Leap Therapeutics is dedicated to advancing its lead product candidates, which target key pathways in cancer biology to provide new treatment options for patients.